Former U.S. Sen. Bob Dole, the elder statesman of Kansas Republican politics, has been diagnosed with advanced lung cancer, he said in a statement Thursday.
Dole, 97, who represented Kansas in the U.S. Senate from 1969 to 1996 and who ran for president in 1996, said he will begin treatment Monday. While I certainly have some hurdles ahead, I also know that I join millions of Americans who face significant health challenges on their own, Dole said in a statement.
About 40% of all lung cancer diagnoses fall into the stage four bracket, according to the Cancer Treatment Centers of America. The five-year survival rate for those diagnoses is 10%.
Bob Dole, longtime Kansas Republican senator, has advanced lung cancer freep.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freep.com Daily Mail and Mail on Sunday newspapers.
Full Year and Fourth Quarter Highlights:
CVS Health logo (PRNewsFoto/CVS Health)
Full year total revenues increased to $268.7 billion, up 4.6% compared to prior year
Full year and fourth quarter GAAP diluted earnings per share from continuing operations of $5.47 and $0.75
Full year and fourth quarter Adjusted EPS of $7.50 and $1.30
Generated full year cash flow from operations of $15.9 billion
Results reflect COVID-19 impacts and related investments
2021 Full Year Guidance:
Adjusted EPS in the range of $7.39 to $7.55
Cash flow from operations in the range of $12.0 billion to $12.5 billion
CVS Health Corporation (NYSE: CVS) today announced operating results for the three months and year ended December 31, 2020.
Beyond COVID-19: Can mRNA Treat Diseases, Too? medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Sumitomo Dainippon Pharma Oncology Announces Phase 3 CanStem303C Study of Napabucasin Fails to Reach Primary Endpoints in Patients with Previously Treated Metastatic Colorectal Cancer
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Feb. 9, 2021 /PRNewswire/ Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the CanStem303C study evaluating the efficacy and safety of investigational agent napabucasin when given in combination with FOLFIRI with or without bevacizumab in patients with previously treated metastatic colorectal cancer failed to reach the primary endpoints of overall survival (OS). Napabucasin in combination with FOLFIRI failed to show significant OS improvement in the general study population and in patients whose tumor was positive for the phosphorylated signal transducer and activator of transcription 3 (pSTAT3) biomarker.